Literature DB >> 18311550

[Direct thrombin inhibitors: pharmacology and application in cardiovascular anesthesia].

S A Kozek-Langenecker1.   

Abstract

The options for drug-controlled anticoagulation are becoming noticeably more manifold. In the area of anaesthesiology and intensive care, there are furthermore special disease patterns, such as heparin-induced thrombocytopenia (HIT) to be known, diagnosed and treated. This article gives a review of the substance groups of the direct thrombin inhibitors (DTI) as alternative anticoagulants for HIT in combination with cardiovascular diseases. For the administration of DTIs, experience and the correct dose are the keys to success and are the deciding factors for the two sides of haemostasis: thrombosis and haemorrhage.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18311550     DOI: 10.1007/s00101-008-1347-5

Source DB:  PubMed          Journal:  Anaesthesist        ISSN: 0003-2417            Impact factor:   1.041


  87 in total

1.  Design and characterization of hirulogs: a novel class of bivalent peptide inhibitors of thrombin.

Authors:  J M Maraganore; P Bourdon; J Jablonski; K L Ramachandran; J W Fenton
Journal:  Biochemistry       Date:  1990-07-31       Impact factor: 3.162

2.  Temporal aspects of heparin-induced thrombocytopenia.

Authors:  T E Warkentin; J G Kelton
Journal:  N Engl J Med       Date:  2001-04-26       Impact factor: 91.245

3.  Immune heparin-induced thrombocytopenia resulting from preceding exposure to heparin catheter flushes.

Authors:  Alaa A Muslimani; Basma Ricaurte; Hamed A Daw
Journal:  Am J Hematol       Date:  2007-07       Impact factor: 10.047

4.  Reversal of hirudin-induced bleeding diathesis by prothrombin complex concentrate.

Authors:  M S Irani; H J White; R G Sexon
Journal:  Am J Cardiol       Date:  1995-02-15       Impact factor: 2.778

5.  Antihirudin antibodies in patients with heparin-induced thrombocytopenia treated with lepirudin: incidence, effects on aPTT, and clinical relevance.

Authors:  P Eichler; H J Friesen; N Lubenow; B Jaeger; A Greinacher
Journal:  Blood       Date:  2000-10-01       Impact factor: 22.113

6.  Severe argatroban-induced coagulopathy in a patient with a history of heparin-induced thrombocytopenia.

Authors:  Hrvoje Gasparovic; Nadia S Nathan; Daniel Fitzgerald; Sary F Aranki
Journal:  Ann Thorac Surg       Date:  2004-12       Impact factor: 4.330

7.  Anticoagulation with bivalirudin during cardiopulmonary bypass in cardiac surgery.

Authors:  Julio C Vasquez; Anna Vichiendilokkul; Syed Mahmood; Frank A Baciewicz
Journal:  Ann Thorac Surg       Date:  2002-12       Impact factor: 4.330

Review 8.  Some objective considerations for the neutralization of the anticoagulant actions of recombinant hirudin.

Authors:  J Fareed; J M Walenga; R Pifarre; D Hoppensteadt; M Koza
Journal:  Haemostasis       Date:  1991

9.  The structure of a complex of recombinant hirudin and human alpha-thrombin.

Authors:  T J Rydel; K G Ravichandran; A Tulinsky; W Bode; R Huber; C Roitsch; J W Fenton
Journal:  Science       Date:  1990-07-20       Impact factor: 47.728

10.  Argatroban therapy does not generate antibodies that alter its anticoagulant activity in patients with heparin-induced thrombocytopenia.

Authors:  Jeanine M Walenga; Sarfraz Ahmad; Debra Hoppensteadt; Omer Iqbal; Marcie J Hursting; Bruce E Lewis
Journal:  Thromb Res       Date:  2002-03-01       Impact factor: 3.944

View more
  2 in total

Review 1.  [Cardiopulmonary bypass in cardiac surgery].

Authors:  T Baehner; O Boehm; C Probst; B Poetzsch; A Hoeft; G Baumgarten; P Knuefermann
Journal:  Anaesthesist       Date:  2012-10       Impact factor: 1.041

2.  [Heparin-induced thrombocytopenia type II with thrombosis in an intensive care patient: therapy management using the direct thrombin inhibitor argatroban].

Authors:  S Heil
Journal:  Anaesthesist       Date:  2009-11       Impact factor: 1.041

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.